SCHEMBL10075747

SCHEMBL10075747

CC(=O)O/N=C(\C)C(=O)c1cccc(Sc2ccc(OCCO)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.40
NR1I2 O75469 1/20 0.34
LMNA P02545 4/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
MAPK1 P28482 1/20 0.33
MAPT P10636 1/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 1/20 0.33
RECQL P46063 1/20 0.33
ADORA1 P30542 1/20 0.33
MEN1 O00255 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
FAAH O00519 1/20 0.32
CYP19A1 P11511 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CYP3A4 P08684 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10075743 0.89 CHEK2 (0.37) GAALMNAL3MBTL1MAPK1ALDH1A1
SCHEMBL22639048 0.89 GAA (0.43) GAANR1I2LMNAL3MBTL1MAPK1
SCHEMBL10075727 0.89 GAA (0.43) GAANR1I2LMNAL3MBTL1MAPK1
SCHEMBL20783443 0.89 GAA (0.43) GAANR1I2LMNAL3MBTL1MAPK1
SCHEMBL10075725 0.86 SLC7A5 (0.38) GAALMNAL3MBTL1MAPTALDH1A1
SCHEMBL20709650 0.84 PLA2G4B (0.37) GAAFAAH
SCHEMBL10075722 0.84 SLC7A5 (0.40) GAALMNAL3MBTL1ALDH1A1HPGD
SCHEMBL10075730 0.83 L3MBTL1 (0.42) GAALMNAL3MBTL1MAPTHPGD
SCHEMBL10075731 0.83 GAA (0.35) GAANR1I2LMNAL3MBTL1MAPT
SCHEMBL10075784 0.83 PPARD (0.37) GAALMNASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586827-B1 CURABLE RESIN COMPOSITION ADEKA CORP (JP) 2017-12-27 EP disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
EP-2586827-A1 CURABLE RESIN COMPOSITION Adeka Corporation (JP) 2013-05-01 EP disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
EP-2327689-B1 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORP (JP) 2012-02-29 EP disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
EP-2327689-A1 Oxime ester compound and photopolymerization initiator containing the same Adeka Corporation (JP) 2011-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME OXER1, OR10J3, CDK11B GAA 4794/4885NR1I2 639/4885LMNA 3014/4885
US-20120115972-A1 CURING RESIN COMPOSITION LTA, LOXL1, PLOD2 GAA 3567/4885NR1I2 4008/4885LMNA 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.